Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RIBOFAST
- Development stage
- Unknown
- Lead developer
- Iromed Group
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
RIBOFAST is a CE-marked ophthalmic solution developed by Iromed Group S.r.l. for use in corneal cross-linking (CXL) procedures. It is a patented, dextran-free formulation containing 0.1% riboflavin as the active photosensitizer and Vitamin E TPGS (d-alpha-tocopheryl polyethylene glycol-1000 succinate) as a corneal penetration enhancer. The product is applied surgically to the cornea and used in conjunction with UV-A light irradiation to treat progressive keratoconus, corneal ectasias (including post-refractive surgery ectasias), pellucid marginal degeneration, and infectious keratitis. The mechanism involves the activation of riboflavin by UV-A light, which induces the formation of covalent bonds between corneal collagen fibers, thereby increasing the biomechanical stability and strength of the corneal stroma. RIBOFAST is compatible with both epithelium-on and epithelium-off protocols and is specifically optimized for use with Iromed's Custom Fast CXL protocol and the CF X-LINKER system.
- Brand names
- RIBOFAST
- Other names
- Ribofast
Beyond the preview
Go deeper on RIBOFAST.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RIBOFAST.